Enliven Therapeutics (ELVN) Free Cash Flow (2019 - 2026)
Enliven Therapeutics has reported Free Cash Flow over the past 8 years, most recently at -$19.3 million for Q1 2026.
- Quarterly results put Free Cash Flow at -$19.3 million for Q1 2026, up 20.11% from a year ago — trailing twelve months through Mar 2026 was -$65.6 million (up 11.35% YoY), and the annual figure for FY2025 was -$70.5 million, up 3.79%.
- Free Cash Flow reached -$19.3 million in Q1 2026 per ELVN's latest filing, down from -$15.8 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$6.5 million in Q3 2022 and bottomed at -$24.1 million in Q1 2025.
- Median Free Cash Flow over the past 5 years was -$15.8 million (2025), compared with a mean of -$15.1 million.
- The largest annual shift saw Free Cash Flow soared 40.73% in 2022 before it plummeted 148.09% in 2023.
- Over 5 years, Free Cash Flow stood at -$8.2 million in 2022, then plummeted by 51.54% to -$12.5 million in 2023, then crashed by 37.67% to -$17.2 million in 2024, then increased by 7.93% to -$15.8 million in 2025, then decreased by 21.8% to -$19.3 million in 2026.
- Business Quant data shows Free Cash Flow for ELVN at -$19.3 million in Q1 2026, -$15.8 million in Q4 2025, and -$13.4 million in Q3 2025.